Misonix.jpg
Misonix Reports Fiscal 2021 Third Quarter Financial Results
May 06, 2021 16:01 ET | MISONIX, Inc.
FARMINGDALE, N.Y., May 06, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and...
ARC logo.png
Wound Care Centers Market Value Predicted To Reach US$ 53.5 Billion By 2027: Acumen Research And Consulting
May 04, 2021 12:13 ET | Acumen Research and Consulting
LOS ANGELES, May 04, 2021 (GLOBE NEWSWIRE) -- The Global Wound Care Centers Market is expected to grow at a CAGR of around 6.2% from 2020 to 2027 and reach the market value of over US$ 53.5 Bn by...
ARC logo.png
Wound Management Market Value Forecasted To Reach US$ 26.2 Billion By 2027: Acumen Research And Consulting
April 07, 2021 11:51 ET | Acumen Research and Consulting
LOS ANGELES, April 07, 2021 (GLOBE NEWSWIRE) -- The Global Wound Management Market is expected to grow at a CAGR of around 4.7% from 2020 to 2027 and reach the market value of over US$ 26.2 Bn by...
Logo_DEBx Medical.png
DEBx Medical Receives CE Mark Clearance and ISO 13485 Certification for Debrichem®, a Novel Desiccant Gel for Chemical Debridement to Initiate Healing in Infected, Chronic Wounds
February 25, 2021 03:30 ET | DEBx Medical B.V.
Debrichem® offers a very effective, alternative approach to chronic wound care, initiating healing in more than 90 % of cases after one application1CE mark and ISO 13485:2016 certification are...
DEBx Medical recibe la autorización de llevar la marca CE y la certificación ISO 13485 para Debrichem®, un novedoso gel desecante para el desbridamiento químico que inicia la cicatrización de heridas infectadas y crónicas
February 25, 2021 03:30 ET | DEBx Medical B.V.
Debrichem® ofrece un enfoque alternativo muy eficaz en el cuidado de las heridas crónicas, iniciando la cicatrización en más del 90% de los casos tras una sola aplicación1La marca CE y la...
Unknown.png
Arch Therapeutics Announces Closing of $6.9 Million Private Placement
February 18, 2021 07:50 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today...
Misonix.jpg
Misonix Reports Fiscal 2021 Second Quarter Financial Results
February 04, 2021 16:01 ET | MISONIX, Inc.
FARMINGDALE, N.Y., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and...
Unknown.png
Arch Therapeutics to Present at the H.C. Wainwright BioConnect Conference, January 11 - 14, 2021
January 05, 2021 07:55 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced...
Unknown.png
Arch Therapeutics Announces Distribution Agreement with Buffalo Supply, Inc.
January 04, 2021 07:50 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced...
Misonix.jpg
Misonix Announces the Second Largest U.S. Commercial Payer Has Provided Coverage for TheraSkin® to Treat All Lower Extremity Dermal Wounds Adding 32 Million New Covered Lives
December 18, 2020 10:14 ET | MISONIX, Inc.
FARMINGDALE, N.Y., Dec. 18, 2020 (GLOBE NEWSWIRE) -- 2020) – Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that...